Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 1.00 |
| ▸ | MMP3 | P08254 | 5/20 | 1.00 |
| ▸ | MMP9 | P14780 | 2/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 4/20 | 0.76 |
| ▸ | MMP7 | P09237 | 1/20 | 0.69 |
| ▸ | MMP8 | P22894 | 1/20 | 0.69 |
| ▸ | MMP13 | P45452 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6850869 | 1.00 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL10429973 | 0.90 | MMP1 (0.82) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL10429916 | 0.87 | MMP1 (0.77) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL10451735 | 0.86 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL15505966 | 0.86 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL10451722 | 0.84 | MMP1 (0.83) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL9650310 | 0.83 | MMP1 (0.86) | MMP1MMP3MMP9ADAM17 | |
| SCHEMBL7276467 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17 | |
| SCHEMBL7284842 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 | |
| SCHEMBL7278285 | 0.82 | MMP1 (1.00) | MMP1MMP3MMP9ADAM17MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646198-A1 | MK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| CN-119685215-A | Metazoan preparation for pets and preparation method and application thereof | 内蒙古科拓微生态科技发展有限公司 | 2025-03-25 | — | — | CN | claimed |
| WO-2024148060-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | WO | claimed |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102959-A1 | METHODS FOR EXTRUDING ELASTOMERIC COMPOSITIONS | CABOT CORP (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260103572-A1 | METHODS FOR PREPARING ELASTOMER COMPOSITES WITH MIXER VENTILATION | CABOT CORP (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260092160-A1 | METHODS OF PREPARING A COMPOSITE HAVING ELASTOMER AND FILLER | BEYOND LOTUS LLC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4646198-A1 | MK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12351587-B2 | Bicyclic compound as RIP-1 kinase inhibitor and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2025-07-08 | — | — | US | disclosed |
| US-12344728-B2 | Methods of preparing a composite having elastomer and filler | BEYOND LOTUS LLC (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2022125679-A1 | METHODS OF PREPARING A COMPOSITE HAVING ELASTOMER, FILLER, AND LINKING AGENTS | BEYOND LOTUS LLC (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| CN-111937319-B | Communication method, communication device and system | 华为技术有限公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3978492-A1 | BICYCLIC COMPOUND AS RIP-1 KINASE INHIBITOR AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2022-04-06 | — | — | EP | disclosed |
| CN-114206571-A | Method for producing a composite comprising an elastomer and a filler | 超越莲花有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11277176-B2 | Communication method, communications apparatus, and communications system | HUAWEI TECHNOLOGIES CO., LTD. (CN) | 2022-03-15 | — | — | US | disclosed |
| CN-114174399-A | Tire tread | 超越莲花有限责任公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20220061324-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-03-03 | — | — | US | disclosed |
| CN-114008038-A | Bicyclofused compound as RIP-1 kinase inhibitor and application thereof | 南京明德新药研发有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103572-A1 | METHODS FOR PREPARING ELASTOMER COMPOSITES WITH MIXER VENTILATION | EXOSC9, RPL30, EXOSC5 | MMP1 1878/4885MMP3 2658/4885MMP9 2121/4885 |
| US-12351587-B2 | Bicyclic compound as RIP-1 kinase inhibitor and application thereof | RIPK1, RIPK2, RIPK3 | MMP1 2969/4885MMP3 3414/4885MMP9 2580/4885 |
| US-11319305-B2 | Pyrimidine sulfamide derivative and preparation method and medical application thereof | TBXA2R, P2RY11, TPMT | MMP1 4392/4885MMP3 4737/4885MMP9 4432/4885 |
| US-20220061324-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | DDT, ACHE, AADAC | MMP1 4125/4885MMP3 4144/4885MMP9 4562/4885 |
| US-20260125397-A1 | MK2 DEGRADERS AND USES THEREOF | NR2C2, NR3C2, OXER1 | MMP1 361/4885MMP3 1205/4885MMP9 1387/4885 |
| US-20260092160-A1 | METHODS OF PREPARING A COMPOSITE HAVING ELASTOMER AND FILLER | COL2A1, COL14A1, COL1A1 | MMP1 1175/4885MMP3 587/4885MMP9 1108/4885 |
| US-20260102959-A1 | METHODS FOR EXTRUDING ELASTOMERIC COMPOSITIONS | SMCHD1, VCP, NSF | MMP1 1157/4885MMP3 1680/4885MMP9 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.